8-K: Journey Medical Reaffirms Guidance and Announces Emrosi Commercial Launch Plan

Journey Medical Corporation reaffirms its financial guidance for 2024 and announces the commercial launch plan for its newly approved dermatological product, Emrosi.

Summary

• Journey Medical Corporation announced on February 5, 2025, that it expects to report $20.3 million in cash and cash equivalents as of December 31, 2024.
• The company is reaffirming its previously issued guidance for the full year ended December 31, 2024, which includes net product revenue of $55 to $60 million.
• Selling, general, and administrative expenses are expected to be in the range of $39 to $42 million.
• Research and development expenses are projected to be between $8 and $10 million.
• These estimates are based on information currently available to management, and actual results are not expected to vary materially.
• Journey Medical will host a conference call on February 5, 2025, to provide an update on the commercial launch plan for Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg), a recently approved dermatological product.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the reaffirmation of financial guidance and the commercial launch of a new product with superior efficacy data. However, risks related to competition, regulation, and the potential need for additional capital temper the overall outlook.

Positives

• The company has a strong cash position with $20.3 million expected as of December 31, 2024.
• The company is reaffirming its financial guidance for 2024.
• Emrosi received FDA approval in November 2024, on time and with first-cycle review.
• Emrosi has shown superior efficacy compared to Oracea and placebo.
• The company has an established dermatology sales force to support the launch of Emrosi.
• The company has a plan to drive dermatologist adoption of Emrosi through various strategies.

Negatives

• The document mentions the company's potential need to raise additional capital.
• Fortress controls a voting majority of the company's common stock, which could be detrimental to other shareholders.
• The company operates in a heavily regulated industry, and future legislation could impact operations.
• The company's revenue is heavily dependent on sales of dermatology products.

Risks

• The company's products and product candidates are subject to time and cost-intensive regulation and clinical testing.
• A substantial portion of sales derive from products that may face generic competition.
• Competition could limit the commercial opportunity and profitability of the company's products.
• The company relies on third parties for several aspects of its operations.
• The company's business and operations could suffer in the event of computer system failures or cyber-attacks.
• The company faces substantial doubt about its ability to continue as a going concern.
• Major public health issues, epidemics, or pandemics could affect product revenues and clinical trials.

Future Outlook

Journey Medical is focused on the commercial launch of Emrosi and expects it to become the new standard of care in rosacea therapy. The company is also working on payer access and continuous payer outreach to improve covered claims.

Management Comments

• Management believes that Emrosi has the potential to become the standard of care for inflammatory lesions of rosacea.
• Management is focused on driving dermatologist adoption of Emrosi through various educational and promotional programs.

Industry Context

The rosacea market is large and growing, with an estimated 16.5 million Americans affected. The company is positioning Emrosi as a superior oral treatment option compared to existing treatments like Oracea, which had peak TRx (total prescriptions) of 769K in 2012.

Comparison to Industry Standards

• Oracea (doxycycline 40mg) was the first and only FDA-approved oral medication for rosacea before Emrosi.
• Oracea achieved over 700,000 TRx by year 5 after launch and peaked at 769,000 TRx in 2012.
• Emrosi demonstrated superior efficacy over Oracea in clinical trials.
• Emrosi is priced at $1,298 WAC (Wholesale Acquisition Cost) in 2025, while Oracea is priced at $914 WAC (2024) and its generic equivalent is priced at $783 WAC (2024).

Stakeholder Impact

• Shareholders can expect updates on the commercial launch of Emrosi and the company's financial performance.
• Customers (patients) will have access to a new treatment option for rosacea with demonstrated superior efficacy.
• Employees will be involved in the commercial launch and promotion of Emrosi.

Next Steps

• Journey Medical will host a conference call on February 5, 2025, to provide an update on the commercial launch plan for Emrosi.
• The company will exhibit at AAD 2025 in March.
• Direct promotion of Emrosi will begin in early April.

Key Dates